Skip to main content
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Nov 24, 2021

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
audience learn

Day 4 Report from ACR21

Nov 10, 2021

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
Nov 09, 2021
IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Nov 09, 2021
IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
TheDaoIndex @KDAO2011( View Tweet )
Nov 09, 2021
Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 09, 2021
Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts

Olga Petryna @DrPetryna( View Tweet )

Nov 09, 2021
After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts ⭐️TNFi most common tx ⭐️28% pts not on any tx⭐️ #ACR21 @RheumNow Abs#1810https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
ACR Best

ACR21 Best Abstracts We Saw - Day 3 (Monday)

Nov 08, 2021

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

Read Article
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24. Reassuring data. @RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
Nov 08, 2021
AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 08, 2021
Study on enthesitis response to biologic Rx ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab ⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab 🔰Superiority of TNFi versus secukinumab in regards to active enthesitis Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
swethaann23 @swethaann23( View Tweet )
Nov 08, 2021
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression. #Abs0909 #ACR21 @RheumNow https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh
Mrinalini Dey @DrMiniDey( View Tweet )
Nov 07, 2021
⁦@JointMD⁩ shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. ⁦@RheumNow⁩ #acr21 https://t.co/mVw05iFPhF

TheDaoIndex @KDAO2011( View Tweet )

Nov 06, 2021
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Nov 06, 2021

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
PSO.Palmoplantar.jpg

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

Oct 28, 2021

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or

Read Article
SI,sacroiliitis,erosion

TICOSPA - Does Treat to Target Work in Spondyloarthritis?

Oct 18, 2021

Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).

Read Article
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj
Dr. John Cush @RheumNow( View Tweet )
Oct 17, 2021
RheumNow Podcast square

RheumNow Podcast – Quackademia (10.15.2021)

Oct 14, 2021

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
×